Valuation: Kinarus Therapeutics Holding AG

Market Cap 4.72M 5.69M 4.99M 4.3M 8.05M 545M 8.1M 56.44M 21.86M 279M 21.37M 20.91M 896M P/E 2022
-0.23x
P/E 2023 -0.01x
Enterprise Value 4.71M 5.68M 4.98M 4.29M 8.03M 544M 8.09M 56.33M 21.82M 278M 21.33M 20.87M 894M EV / Sales 2022
4,318,722x
EV / Sales 2023 -
Free-Float
-
Yield 2022 *
-
Yield 2023 -
1 day-11.75%
Current month+4.79%
Current year+4.79%
3 years 0.9
Extreme 0.895999
33.15
5 years 0.9
Extreme 0.895999
230.27
10 years 0.9
Extreme 0.895999
230.27

Financials

2022 2023
Net sales 3.34 4.03 3.53 3.04 5.69 385.8 5.73 39.92 15.46 197.1 15.11 14.79 633.45 -
Net income -34.73M -41.91M -36.77M -31.65M -59.25M -4.02B -59.67M -416M -161M -2.05B -157M -154M -6.6B -49.38M -59.58M -52.28M -45M -84.24M -5.71B -84.84M -591M -229M -2.92B -224M -219M -9.38B
Net Debt 1.66M 2M 1.76M 1.51M 2.83M 192M 2.85M 19.84M 7.68M 97.96M 7.51M 7.35M 315M -9K -10.86K -9.53K -8.2K -15.35K -1.04M -15.46K -108K -41.71K -532K -40.77K -39.89K -1.71M
Logo Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Employees
-
Sector
-
Date Price Change
28/09/26 CHF 16.90 -11.75%
25/09/26 CHF 19.15 +1.32%
24/09/26 CHF 18.90 -0.53%
23/09/26 CHF 19.00 -0.78%
22/09/26 CHF 19.15 +3.51%
  1. Stock Market
  2. Stocks
  3. CURE Stock